Key result
A new manufacturing process and stable liquid formulation for the RV3-BB rotavirus vaccine achieved a target cost of goods of ≤$3.50 per three-dose course at a clinical dose of ≤6.3 log10 FFU.
Why the study?
Over 82 million infants lack access to rotavirus vaccines due to cost, manufacturing capacity, and suboptimal efficacy, requiring a well-documented and low-cost manufacturing process for the RV3-BB vaccine candidate.
This is the authors' abstract. We don't add key points for this paper.
Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of ≤$3.50 per course of three doses was set based on predicted market requirements. COGs modelling was leveraged to develop a process using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and shortening process time to maximise output. Stable candidate liquid formulations were developed allowing two-year storage at 2–8 °C. In addition, the formulation potentially renders needless the pretreatment of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose of ≤6.3 log10 FFU, the COGs target of ≤$3.50 per three dose course was met. At a clinical dose of 6.5 log10 FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production.
Answers are grounded in this paper and cite their sources.
A new manufacturing process and liquid formulation for the RV3-BB rotavirus vaccine meets target cost of goods and stability requirements, potentially improving global vaccine access.
No takes yet. Share an insight, caveat, or question.
Hamidi et al. (2021) studied Rotavirus gastroenteritis. RV3-BB vaccine was evaluated on Cost of goods (COGs). A new manufacturing process and stable liquid formulation for the RV3-BB rotavirus vaccine achieved a target cost of goods of ≤$3.50 per three-dose course at a clinical dose of ≤6.3 log10 FFU.
Synapse has enriched 10 related papers. Consider them for comparative context: